Positive neoadjuvant libtayo® (cemiplimab) monotherapy data in resectable cutaneous squamous cell carcinoma presented at esmo and published in nejm

63% combined pathologic response rate for neoadjuvant libtayo monotherapy in stage ii to iv resectable cscc per primary analysis of a confirmatory phase 2 trial tarrytown, n.y. , sept. 12, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive clinical data for an investigational regimen of pd-1 inhibitor libtayo® (cemiplimab) as neoadjuvant monotherapy in stage ii to iv resectable cutaneous squamous cell carcinoma (cscc).
REGN Ratings Summary
REGN Quant Ranking